AbbVie News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

01.07.19	Form 8.3 - The Vanguard Group, Inc.: AbbVie plc (EQS Group)
28.06.19	Form 8.3 - The Vanguard Group, Inc.: AbbVie plc (EQS Group)
27.06.19	Form 8.3 - The Vanguard Group, Inc.: AbbVie plc (EQS Group)
25.06.19	AbbVie To Buy Allergan In $63 Bln Cash, Stock Deal - Quick Facts (RTTNews)
16.05.19	Roche Announces FDA Approval For Expanded Use Of Venclexta - Quick Facts (RTTNews)
24.04.19	Plaque Psoriasis Armamentarium Gets New Addition (RTTNews)
04.04.19	10 Best Selling Drugs Of 2018 (RTTNews)
26.03.19	Biotech Stocks Facing FDA Decision In April (RTTNews)
26.03.19	AbbVie Announces Approval Of SKYRIZI In Japan - Quick Facts (RTTNews)
19.03.19	AbbVie : FDA Places Partial Clinical Hold On All Clinical Trials On Venetoclax (RTTNews)
22.02.19	AbbVie And Voyager Therapeutics Collaborate To Develop Vectorized Antibodies (RTTNews)
20.02.19	FDA Nod For NVO's Hemophilia A Drug, ICPT's NASH Trial Hits Goal, NVTA Abuzz (RTTNews)
28.01.19	What's Making News In These Pharma And Cannabis Stocks Today? (RTTNews)
25.01.19	AbbVie Q4 Results Miss View; Stock Down (RTTNews)
24.12.18	Lupin, AbbVie To Develop Novel Oncology Drug To Treat Hematological Cancers (RTTNews)
30.11.18	Pfizer Reaches Global Agreement With AbbVie; To Withdraw Pending Litigation (RTTNews)
15.11.18	MNK Awaits D-Day, AMEH In Good Health, AXSM To Report ASCEND Data In Jan. (RTTNews)
01.11.18	AbbVie: VENCLYXTO Plus Rituximab Gets Europe Approval To Treat CLL Patients (RTTNews)
25.10.18	Galapagos And AbbVie Restructure CF Collaboration (RTTNews)
23.10.18	ABBV ACHIEVES Goals, HealthStream's CFO Resigns, NTEC On Watch (RTTNews)
19.10.18	AbbVie CFO William Chase Plans To Retire In Mid-2019 (RTTNews)
18.10.18	AbbVie Announces Resolution Of HUMIRA Patent Disputes With Fresenius Kabi (RTTNews)
12.10.18	Sandoz, AbbVie Announce Global Resolution Of Humira Patent Disputes (RTTNews)
20.09.18	Mylan To Launch Biosimilar To Humira In Europe - Quick Facts (RTTNews)
19.09.18	California Sues AbbVie Alleging Kickbacks For Humira (RTTNews)
23.08.18	Bristol-Myers: FDA To Review SBLA For Empliciti With Pomalidomide, Dexamethasone (RTTNews)
22.08.18	AbbVie Announces Positive Results From Phase 3 Extension Study On Elagolix (RTTNews)
17.08.18	New Drugs Approved In July (RTTNews)
24.07.18	AbbVie Reports FDA Approval Of ORILISSA - Quick Facts (RTTNews)
12.07.18	Genentech Announces Submission Of SNDA For Venclexta - Quick Facts (RTTNews)
11.07.18	AbbVie Updates On Phase 3 Study Of Ibrutinib In Blood Cancer DLBCL (RTTNews)
01.07.18	AbbVie Says Will Appeal $448 Mln Antitrust Judgment (RTTNews)
29.06.18	Biotech Stocks Facing FDA Decision In July (RTTNews)
26.06.18	AbbVie Extends Collaboration With Alphabet-backed Life Sciences Company Calico (RTTNews)
19.06.18	8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-Annual "Week of Possibilities" (PR Newswire)
15.06.18	AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd... (PR Newswire)
15.06.18	AbbVie Declares Quarterly Dividend (PR Newswire)
13.06.18	AbbVie Presents Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018) (PR Newswire)
08.06.18	AbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma... (PR Newswire)
05.06.18	Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis (PR Newswire)
05.06.18	Arjo strengthens position within Long-Term Care in North America (PR Newswire)
04.06.18	AbbVie Announces Final Results of Tender Offer (PR Newswire)
03.06.18	Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL) (PR Newswire)
01.06.18	Phase 3 IMBRUVICA® (ibrutinib) Data Suggest Improved Treatment Outcomes in Waldenström's Macroglobulinemia (WM), a Rare Form of Blood Cancer, in Combination with Rituximab versus Rituximab Alone (PR Newswire)
31.05.18	StarfishETL Recognized for IT Management Software Excellence by FinancesOnline Directory (PR Newswire)
31.05.18	AbbVie to Present New Data from Several Investigational Studies of Venetoclax as Monotherapy or in Combination for the Management of a Number of Difficult-to-Treat Blood Cancers at 23rd European... (PR Newswire)
30.05.18	AbbVie Announces Preliminary Results of Tender Offer (PR Newswire)
29.05.18	AbbVie to Present at the Goldman Sachs 39th Annual Global Healthcare Conference (PR Newswire)
24.05.18	AbbVie Says Phase 3 ILLUMINATE Trial Met Primary Endpoint Of Improvement In PFS (RTTNews)
24.05.18	IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

15.01.25		Pluszeichen in New York: S&P 500 zum Ende des Mittwochshandels in der Gewinnzone
15.01.25		Börse New York in Grün: S&P 500 legt zu
15.01.25		Freundlicher Handel in New York: So performt der S&P 500 am Mittag
15.01.25		Aufschläge in New York: S&P 500 zum Start stärker
11.11.24		Börse New York in Grün: S&P 500 zum Handelsende freundlich
11.11.24		Optimismus in New York: S&P 500 am Nachmittag mit Kursplus
11.11.24		NYSE-Handel: S&P 500 mittags freundlich
11.11.24		Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen

15.01.25

Pluszeichen in New York: S&P 500 zum Ende des Mittwochshandels in der Gewinnzone

15.01.25

Börse New York in Grün: S&P 500 legt zu

15.01.25

Freundlicher Handel in New York: So performt der S&P 500 am Mittag

15.01.25

Aufschläge in New York: S&P 500 zum Start stärker

11.11.24

Börse New York in Grün: S&P 500 zum Handelsende freundlich

11.11.24

Optimismus in New York: S&P 500 am Nachmittag mit Kursplus

11.11.24

NYSE-Handel: S&P 500 mittags freundlich

11.11.24

Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Kuehne+Nagel Int	206.70	2.43 %	K V
UBS Group	31.75	1.99 %	K V
Lonza Grp	563.20	1.59 %	K V
Sika	227.20	1.16 %	K V
Alcon	77.98	1.01 %	K V
Swisscom	512.50	0.00 %	K V
Novartis	89.23	-0.10 %	K V
Swiss Re	135.60	-0.18 %	K V
Swiss Life Hldg	721.80	-0.50 %	K V
Zurich Insur Gr	530.40	-1.67 %	K V

Nachrichten zu AbbVie Inc

Aktien Top/Flop

AbbVie Peer Group Nachrichten

Meistgelesene Nachrichten